Eledon Pharmaceuticals (ELDN) vs Lyell Immunopharma (LYEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Eledon Pharmaceuticals (ELDN) has outperformed Lyell Immunopharma (LYEL) over the past year, losing 11.4% versus a loss of 51.6%. Over five years, ELDN leads with a -57.0% price change compared with -96.8% for LYEL. Lyell Immunopharma is the larger company by market cap ($204.0 million vs $193.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELDN | LYEL |
|---|---|---|
| Share price | $2.39 | $8.33 |
| Market cap | $193.81M | $204.01M |
| 1-day change | -1.45% | -2.75% |
| YTD return | +60.26% | -72.19% |
| 1-year return | -11.36% | -51.61% |
| 5-year return | -57.02% | -96.78% |
| EPS (TTM) | $-0.90 | $-12.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.60 | $45.00 |
| 52-week low | $1.35 | $8.28 |
| Distance from 52-week high | -48.15% | -81.50% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +277.36% | +355.02% |
| Average volume | 944.26K | 144.81K |
| Shares outstanding | 81.26M | 24.51M |
| Employees | 33 | 161 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ELDN has outperformed LYEL by 40.3 percentage points over the past year.
About Eledon Pharmaceuticals
ELDN stock →Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
About Lyell Immunopharma
LYEL stock →Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees
ELDN vs LYEL FAQ
Which is bigger, Eledon Pharmaceuticals or Lyell Immunopharma?
Lyell Immunopharma (LYEL) is larger, with a market capitalization of $204.01M compared with $193.81M for Eledon Pharmaceuticals (ELDN).
Which stock has performed better over the past year, ELDN or LYEL?
ELDN returned -11.36% over the past 12 months, compared with -51.61% for LYEL (price return, excluding dividends). Past performance does not predict future results.
Are Eledon Pharmaceuticals and Lyell Immunopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.